Palisade Bio(PALI)

CARLSBAD, CABiotechnology1 H-1B visas (FY2023)

Focus: Palisade Bio is a public-stage biotechnology company focused on small molecule therapeutics, primarily in oncology and gastrointestinal indications. The company operates at a pre-commercial scale with minimal revenue ($250K in FY2024) and a lean R&D footprint.

Oncology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Palisade Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Palisade Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Pipeline & Clinical Trials

PALI-2108

Ulcerative Colitis (UC)

Phase 1

Clinical Trials (1)

NCT06663605Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.

Phase 1

Help build intelligence for Palisade Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage drug discovery environment with multi-program portfolio across oncology and GI diseases offering exposure to diverse therapeutic areas
Public company status provides liquidity and potential upside via equity participation without pre-revenue biotech extinction risk
Focused pipeline with Phase 3 asset (LB1148 in Ileus) creates near-term inflection points and regulatory visibility

Watch Out For

Critically low cash position ($10M FY2025) and accelerating burn rate ($16M R&D spend vs. $250K revenue) creates 6-9 month runway—material restructuring or financing risk imminent
Zero active job openings and no disclosed headcount signal possible hiring freeze or imminent contraction; H1B sponsorship minimal (1 approval in 2023)

Generated by Claude from Palisade Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

PALI-2108

Fibrostenotic Crohn's Disease

Phase 1

Clinical Trials (1)

NCT07428096A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease

Phase 1

LB1148

COVID-19

Phase 2

Clinical Trials (1)

NCT04390217LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia

Phase 2

LB1148

Ileus

Phase 2

Clinical Trials (1)

NCT02836470A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

Phase 2

LB1148

Septic Shock

Phase 2

Clinical Trials (1)

NCT02317549Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

Phase 2

LB1148

Ileus

Phase 3

Clinical Trials (1)

NCT05470387A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Immunology, Gastroenterology, Infectious Diseases

H-1B (2023): 1 approval

SEC Filings: 2 available

Therapeutic Area Focus

Immunology

2 pipeline

Gastroenterology

1 pipeline

Infectious Diseases

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$0100%

R&D Spend

$16M132%

Net Income

-$14M

Cash

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo